vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and CIVISTA BANCSHARES, INC. (CIVB). Click either name above to swap in a different company.
BillionToOne, Inc. is the larger business by last-quarter revenue ($83.5M vs $47.3M, roughly 1.8× CIVISTA BANCSHARES, INC.). CIVISTA BANCSHARES, INC. runs the higher net margin — 31.7% vs 6.8%, a 24.9% gap on every dollar of revenue.
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Civista Bancshares, Inc. is a US-based bank holding company operating primarily across the Midwest region. It provides a full suite of personal and commercial banking services including deposit accounts, mortgage, consumer and commercial lending products, as well as wealth management solutions, serving retail consumers, small and medium-sized local businesses and community client segments.
BLLN vs CIVB — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $47.3M |
| Net Profit | $5.7M | $15.0M |
| Gross Margin | 69.9% | — |
| Operating Margin | 11.5% | — |
| Net Margin | 6.8% | 31.7% |
| Revenue YoY | 117.4% | — |
| Net Profit YoY | 138.3% | 47.4% |
| EPS (diluted) | $0.10 | $0.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $47.3M | ||
| Q4 25 | — | $46.3M | ||
| Q3 25 | $83.5M | $44.2M | ||
| Q2 25 | — | $41.4M | ||
| Q1 25 | — | $40.6M | ||
| Q4 24 | — | $40.4M | ||
| Q3 24 | $38.4M | $39.3M | ||
| Q2 24 | — | $38.1M |
| Q1 26 | — | $15.0M | ||
| Q4 25 | — | — | ||
| Q3 25 | $5.7M | $12.8M | ||
| Q2 25 | — | $11.0M | ||
| Q1 25 | — | $10.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-14.9M | $8.4M | ||
| Q2 24 | — | $7.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 31.8% | ||
| Q3 25 | 11.5% | 35.4% | ||
| Q2 25 | — | 31.1% | ||
| Q1 25 | — | 29.4% | ||
| Q4 24 | — | 28.2% | ||
| Q3 24 | -32.9% | 25.2% | ||
| Q2 24 | — | 21.2% |
| Q1 26 | — | 31.7% | ||
| Q4 25 | — | — | ||
| Q3 25 | 6.8% | 28.9% | ||
| Q2 25 | — | 26.6% | ||
| Q1 25 | — | 25.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | -38.8% | 21.3% | ||
| Q2 24 | — | 18.5% |
| Q1 26 | — | $0.72 | ||
| Q4 25 | — | $0.59 | ||
| Q3 25 | $0.10 | $0.68 | ||
| Q2 25 | — | $0.71 | ||
| Q1 25 | — | $0.66 | ||
| Q4 24 | — | $0.62 | ||
| Q3 24 | $-1.47 | $0.53 | ||
| Q2 24 | — | $0.45 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | — |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $-239.5M | $553.9M |
| Total Assets | $327.5M | $4.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $195.2M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $553.9M | ||
| Q4 25 | — | $543.5M | ||
| Q3 25 | $-239.5M | $499.0M | ||
| Q2 25 | — | $404.1M | ||
| Q1 25 | — | $397.4M | ||
| Q4 24 | — | $388.5M | ||
| Q3 24 | $-242.9M | $394.4M | ||
| Q2 24 | — | $373.8M |
| Q1 26 | — | $4.3B | ||
| Q4 25 | — | $4.3B | ||
| Q3 25 | $327.5M | $4.1B | ||
| Q2 25 | — | $4.2B | ||
| Q1 25 | — | $4.1B | ||
| Q4 24 | — | $4.1B | ||
| Q3 24 | — | $4.1B | ||
| Q2 24 | — | $4.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | — |
| Free Cash FlowOCF − Capex | $6.5M | — |
| FCF MarginFCF / Revenue | 7.7% | — |
| Capex IntensityCapex / Revenue | 8.8% | — |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $43.3M | ||
| Q3 25 | $13.8M | $19.0M | ||
| Q2 25 | — | $11.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $48.2M | ||
| Q3 24 | — | $12.9M | ||
| Q2 24 | — | $12.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $42.1M | ||
| Q3 25 | $6.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $3.5M | ||
| Q4 24 | — | $44.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 90.9% | ||
| Q3 25 | 7.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 8.5% | ||
| Q4 24 | — | 109.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.5% | ||
| Q3 25 | 8.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 10.4% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | 1.49× | ||
| Q2 25 | — | 1.01× | ||
| Q1 25 | — | 0.36× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | — | 1.73× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
CIVB
| Net Interest Income | $37.8M | 80% |
| Noninterest Income | $9.4M | 20% |
